129Xe MRI in Pediatric Population With BPD

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2026

Primary Completion Date

July 31, 2031

Study Completion Date

December 31, 2031

Conditions
Bronchopulmonary Dysplasia
Interventions
COMBINATION_PRODUCT

MagniXene, hyperpolarized 129Xe MRI

"All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results."

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

lead

Xemed LLC

INDUSTRY